Literature DB >> 27378239

Lung Cancer Deaths in the National Lung Screening Trial Attributed to Nonsolid Nodules.

Rowena Yip1, David F Yankelevitz1, Minxia Hu1, Kunwei Li1, Dong Ming Xu1, Artit Jirapatnakul1, Claudia I Henschke1.   

Abstract

Purpose To validate the recommendation of performing annual follow-up of nonsolid nodules (NSNs) identified by computed tomographic (CT) screening for lung cancer, all cases of lung cancer manifesting as NSN in the National Lung Screening Trial (NLST) were reviewed. Materials and Methods Institutional review board and informed consent were waived for this study. The NLST database was searched to identify all participants with at least one NSN on CT scan with lung cancer as the cause of death (COD) documented by the NLST endpoint verification process. Among the 26 722 participants, 2534 (9.4%) had one or more NSNs, and lung cancer as the COD occurred for 48 participants. On review, 21 of the 48 patients had no NSN in the cancerous lobe, which left 27 patients whose CT scans were reviewed by four radiologists: Group A (n = 12) were cases of lung cancer as the COD because of adenocarcinoma, and group B (n = 15) were cases of lung cancer as the COD because of other cell types. Frequency of lung cancer as the COD because of NSN and the time from randomization to diagnosis within these groups was determined. Results Six of the 12 patients in group A had no NSN in the cancerous lobe whereas the remaining six patients had a dominant solid or part-solid nodule in the lobe that rapidly grew in four patients, was multifocal in one patient, and had a growing NSN in one patient in whom diagnosis was delayed for over 3 years. Five of the 15 patients in group B had no NSN, and for the remaining 10 patients, lung cancer as the COD was not because of NSN. Conclusion It seems unlikely that patients with lung cancer as the COD occurred with solitary or dominant NSN as long as annual follow-up was performed. This lends further support that lung cancers that manifest as NSNs have an indolent course and can be managed with annual follow-up. © RSNA, 2016.

Entities:  

Mesh:

Year:  2016        PMID: 27378239     DOI: 10.1148/radiol.2016152333

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  19 in total

1.  Evidence for Expanding Invasive Mediastinal Staging for Peripheral T1 Lung Tumors.

Authors:  Emily A DuComb; Benjamin A Tonelli; Ya Tuo; Bernard F Cole; Vitor Mori; Jason H T Bates; George R Washko; Raúl San José Estépar; C Matthew Kinsey
Journal:  Chest       Date:  2020-06-26       Impact factor: 9.410

2.  The relationship of cancer characteristics and patient outcome with time to lung cancer diagnosis after an abnormal screening CT.

Authors:  Sushilkumar K Sonavane; Paul Pinsky; Jubal Watts; David S Gierada; Reginald Munden; Satinder P Singh; Hrudaya Nath
Journal:  Eur Radiol       Date:  2017-06-14       Impact factor: 5.315

3.  Adenocarcinoma in pure ground glass nodules: histological evidence of invasion and open debate on optimal management.

Authors:  Gianluca Milanese; Nicola Sverzellati; Ugo Pastorino; Mario Silva
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

4.  Utility of computed tomography lung cancer screening and the management of computed tomography screen-detected findings.

Authors:  Ammar Chaudhry; Maryam Gul; Abbas Chaudhry
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

5.  The natural course of incidentally detected, small, subsolid lung nodules-is follow-up needed beyond current guideline recommendations?

Authors:  Benedikt H Heidinger; Mario Silva; Constance de Margerie-Mellon; Paul A VanderLaan; Alexander A Bankier
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 6.  Controversies on lung cancers manifesting as part-solid nodules.

Authors:  Rowena Yip; Kunwei Li; Li Liu; Dongming Xu; Kathleen Tam; David F Yankelevitz; Emanuela Taioli; Betsy Becker; Claudia I Henschke
Journal:  Eur Radiol       Date:  2017-08-23       Impact factor: 5.315

Review 7.  Appropriate screening intervals in low-dose CT lung cancer screening.

Authors:  Marjolein A Heuvelmans; Matthijs Oudkerk
Journal:  Transl Lung Cancer Res       Date:  2018-06

Review 8.  Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives.

Authors:  Matthijs Oudkerk; ShiYuan Liu; Marjolein A Heuvelmans; Joan E Walter; John K Field
Journal:  Nat Rev Clin Oncol       Date:  2020-10-12       Impact factor: 66.675

Review 9.  Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

10.  Baseline and annual repeat rounds of screening: implications for optimal regimens of screening.

Authors:  Claudia I Henschke; Mary Salvatore; Matthew Cham; Charles A Powell; Larry DiFabrizio; Raja Flores; Andrew Kaufman; Corey Eber; Rowena Yip; David F Yankelevitz
Journal:  Eur Radiol       Date:  2017-10-05       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.